Relay Corp (RLAY) - Market Cap to Net Income Ratio

Symbol and logo of brand Relay Therapeutics Inc (RLAY)

Relay Therapeutics (RLAY) synthesizes anti-tumor agents through the synergy of IT engineering and chemistry, while the P/E ratio visualizes the asset's current market valuation. Proprietary protein modeling algorithms create a significant barrier to entry for competitors. Massive demand for precision oncology determines the future success of targeted molecules, while the -15.00 mark reflects the issuer's latest earnings data.

RLAY relaytx.com: Price to Earnings Ratio in the range 07/04/2022 - 11/11/2026

Comprehensive metric breakdowns and analytics for Relay Pharma (RLAY)

- market price and analyst price targets:
Market Price relaytx.com|RLAY - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Relay Therapeutics, Inc.|RLAY - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Relay Therapeutics|RLAY - Company Net Assets|Market Value to Book Value relaytx.com|RLAY - Cumulative Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Relay Therapeutics|RLAY - Long-Term Debt to Capital|Short-Term Debt to Capital Relay Corp|RLAY - Company Debts|Debt to Net Assets Ratio Relay Therapeutics, Inc.|RLAY - Company Long-Term Debts|Short-Term Indebtedness Relay Therapeutics|Immediate Liquidity relaytx.com
- business earnings and investment ratios data:
RLAY - Net Income|Future Net Profit Relay Therapeutics|RLAY - P/E Multiple|Projected Price to Earnings Ratio Relay Therapeutics Inc|RLAY - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Relay Therapeutics, Inc.|RLAY - Operating profit before deduction of amortization|Earnings per share for the trailing year Relay Therapeutics|RLAY - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months relaytx.com|RLAY - Earnings growth in current year|Expected earnings per share trend next year Relay Therapeutics
Comprehensive company analysis:relaytx.com - RLAY
Finished products of Relay Pharma

Fundamental asset selection requires analyzing the ratio of market capitalization to net income, which determines the cost of one dollar of earnings. This metric reflects the market valuation of business efficiency, where the issuer's P/E ratio compares the current costs of ESG optimization for Relay Therapeutics (RLAY) computing capacities with actual returns, warning the investor of the risks of overpaying for technological potential.

Key competitors

Market Cap to Earnings genmab.com GMAB|P/E Multiple EXEL|Nuvalent Inc (NUVL) - Market Cap to Net Income Ratio|Kymera Therapeutics Inc - Price to Earnings Ratio|IDEAYA Corp (IDYA) - Market Cap to Earnings|ELVN: Price to Earnings Ratio|Company Value to Net Income ORIC (oricpharma.com)|NRIX (Nurix Therapeutics, Inc.) - Price to Earnings Ratio|TYRA: Market Price to Net Income Ratio|VSTM (Verastem Inc) - P/E Multiple|P/E Multiple Monte Rosa Corp|Price to Earnings Ratio Cullinan Therapeutics (CGEM)|IMRX (immuneering.com) - Company Value to Net Income|P/E Multiple CCCC (C4 Therapeutics)|Market Cap to Net Income Ratio Black Diamond Therapeutics, Inc.|Repare Rx - P/E Multiple|Market Cap to Earnings PMV Pharmaceuticals, Inc|KPTI (karyopharm.com) - Price to Earnings Ratio|PPCB: Market Price to Net Income Ratio|BGMS (Bio Green Med Solution) - P/E Multiple|Market Cap to Earnings Aadi Bio AADI|P/E Multiple ALRN|blueprintmedicines.com - Price to Earnings Multiple|GlycoMimetics - Price to Earnings Ratio|Company Value to Net Income SWTX